Clinical Trial Update: Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism [Phase 3]

View source ↗

Summary

Extension trial evaluating the long-term safety and efficacy of dasiglucagon in children with congenital hyperinsulinism has completed Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Hyperinsulinism

Drugs mentioned

• dasiglucagon (dasiglucagon)

Snippet

Sponsor: Zealand Pharma | Conditions: Congenital Hyperinsulinism | Phase 3 | Status: COMPLETED